Examining the Treatment Landscape of Metastatic NSCLC Expressing the Targetable Mutations RET, MET, and KRAS

Program Description

Management of non-small cell lung cancer has significantly evolved with the expanding role of molecular testing to guide treatment decisions. Testing for molecular and immune biomarkers allows for targeted disease management. This discussion focuses on the lesser-known biomarkers RET, MET, and KRAS and their corresponding targeted therapies. Patient education points regarding adherence and adverse effect management will also be reviewed.

Target audience: Health-system and oncology pharmacists

Type of activity: Knowledge
Release date: July 29, 2022
Expiration date: July 29, 2023

Time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non−small cell lung cancer
• Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic non−small cell lung cancer expressing RET, MET, and KRAS mutations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, listen to the podcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant (advisory board): Bristol Myers Squibb

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms